Business Parks & Science Centres



Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Financing › Details

Innovative Medicines Initiative–EU (govt): grant, 201310– funding €8m for GETREAL project by IMI of €16.3m total cost


Period Period 2013-10-01
Region Region EU (European Union)
Organisations Money taker GETREAL project (Incorporating REal-life clinical data into drug development) (IMI, EU, EFPIA 201310–)
  Group Innovative Medicines Initiative (IMI)
  Money source EU (govt)
Products Product drug development
  Product 2 clinical research

Innovative Medicines Initiative (IMI). (3/11/14). "Press Release: New IMI Project to Incorporate Real Life Data into Drug Development". Brussels.

- Incorporating real life clinical data into drug development will assist healthcare decision makers when deciding how best to grant patients access to a new treatment and help pharmaceutical companies take better decisions during drug development.

- €16.3 million GETREAL project brings together industry, academia, regulatory agencies, reimbursement agencies, healthcare budget holders, and patient groups.

The Innovative Medicines Initiative (IMI) has launched a new project called GETREAL that will investigate new ways of integrating data from real life settings, such as clinics, into drug development. This will assist healthcare decision makers when deciding how best to grant patients access to a new treatment and help pharmaceutical companies to take better decisions during drug development.

Once a new drug has been developed, it must be reviewed by both the marketing authorisation and health technology assessment (HTA) bodies. For marketing authorisation, regulators draw on data, mostly from clinical trials, to determine if a drug is safe and works well enough to be authorised for use in patients. For their part, HTA organisations assess the drug's 'relative effectiveness', which is the extent to which a treatment does more good than harm when compared to one or more alternative treatments when provided under normal healthcare circumstances.

Ideally, HTA organisations need data from real life settings, yet there is little guidance on how to generate real world data and integrate this into drug development before launch. This is a serious issue in drug development - even if a drug is approved as safe and efficacious by the regulators, insufficient evidence supporting relative effectiveness at the time of launch may delay, or restrict patient access to new treatments. The challenge, therefore, is to incorporate innovative study designs into the earlier stages of drug research and development, to ensure both regulators and HTA bodies get the data they need. This is where the GETREAL project comes in.

The project brings together for the first time all key stakeholders (industry, academia, regulatory agencies, health technology assessment bodies, healthcare budget holders, and patient groups) to share their perspectives and insights on how effectiveness/relative effectiveness can best be assessed in HTA decision-making processes, and so will pave the way for advancing the development of new approaches for incorporating real life data into drug development.

IMI Executive Director Michel Goldman said: 'Collaboration between these diverse groups can be sensitive. By bringing them together in the safe harbour offered by IMI, GETREAL is in a unique position to reach a greater consensus on these issues to improve the efficiency of R&D and the decision-making processes.'

Working together, these diverse partners will analyse existing processes and methodologies for HTA. GETREAL will also generate a decision-making framework to help pharmaceutical companies design drug development strategies. A significant part of the project is devoted to organising training activities for researchers, healthcare decision makers and other stakeholders on relative effectiveness concepts and how they can be applied.


Notes to Editors

- GETREAL factsheet:
- GETREAL website:

Press contact

Catherine Brett - External Relations Manager
Tel: +32 2 541 8214 - Mobile: +32 484 896227 - E-mail: catherine.brett AT

About IMI

The Innovative Medicines Initiative (IMI) is the world's largest public-private partnership in health. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects. The European Union contributes €1 billion to the IMI research programme, and this is matched by in kind contributions worth at least another €1 billion from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The Innovative Medicines Initiative currently supports 46 projects, many of which are already producing impressive results. The projects are all working to address the biggest challenges in drug development, with the goal of accelerating the development of safer and more effective treatments for patients.

- More info on IMI:
- Follow us on Twitter: @IMI_JU

Record changed: 2017-04-02


Picture [LSE] – The Business Web Portal 600x60px

More documents for Innovative Medicines Initiative (IMI)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

» top